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Melanin-concentrating hormone (MCH) is a hypothalamic neuropeptide that plays an impor-
tant role in feeding behavior. It activates two G-protein-coupled receptors, MCHR1 and
MCHR2, of which MCHR1 is the primary regulator of food intake and energy homeosta-
sis in rodents. In mammalian cells transfected with MCHR1, MCH is able to activate
multiple signaling pathways including calcium mobilization, extracellular signal-regulated
kinase activation, and inhibition of cyclic AMP generation through Gi/o- and Gq-coupled
pathways. Further evidence suggests that MCHR1 is regulated through posttranslational
modifications, which control its intracellular localization and provide appropriate cellular
responses involving G-protein signaling. This review summarizes the current data on the
control of MCHR1 function through glycosylation and phosphorylation, as related to cell
function. Especially, a series of mutagenesis study highlights the importance of complete
glycosylation of MCHR1 for efficient trafficking to the plasma membrane.
Keywords: melanin-concentrating hormone, structure-function relationship, glycosylation, phosphorylation,
G-protein
INTRODUCTION
The G-protein-coupled receptor (GPCR) gene family is one of the
largest families in the mammalian genome. GPCRs are typical hep-
tahelical receptors composed of an extracellular N-terminus, an
intracellular C-terminus, and seven transmembrane bundles con-
nected by three intracellular loops and three extracellular loops.
Activation of GPCRs induces second messenger responses that
change the biochemical properties of the recipient cell and can
modulate not only its electrophysiological responsiveness, but
also its transcriptional activity. Thus, the diverse signaling and
wide array of functions have allowed GPCRs to be employed
in the physiological regulation of nearly all biological functions.
These features coupled with ligands that are chemically highly
specific for the receptors have resulted in the extensive utilization
of GPCR-targeted drug design. Furthermore, the dynamic post-
translational modifications may provide tissue-specific functions,
since distinct cellular environments or agonists can mediate dif-
ferent effects on receptor signaling or regulation of a number of
GPCRs (1–5). Consequently, these regulatory processes may hold
the keys to alternative targets for GPCR research. In this article, we
focus solely on the posttranslational modification of one GPCR,
melanin-concentrating hormone (MCH) receptor, which is one of
the potential targets for obesity research.
ROLE OF MCH IN FOOD INTAKE
Melanin-concentrating hormone was originally discovered as a 17-
amino-acid neuropeptide in the chum salmon pituitary (6). MCH
is secreted from the pituitary into the circulation, and induces pal-
ing of the skin in teleost fish. Mammalian MCH was subsequently
identified as a 19-amino-acid peptide in the rat hypothalamus (7).
Although the peptide structures are highly conserved between fish
and mammals, no direct effects of MCH on skin pigmentation in
mammals are demonstrable. Mammalian MCH is predominantly
synthesized in the brain, especially in the lateral hypothalamus
(LH) and zona incerta with projections to numerous areas in
the brain (8). The LH is classically known as the “hunger cen-
ter,” since lesions in this area produce anorexia and stimulation
of the area leads to overeating. The important role of MCH in
feeding was supported by a study showing that the MCH gene is
overexpressed upon fasting and in ob/ob leptin-deficient mice (9).
Moreover, direct intracerebroventricular administration of MCH
increases food intake in rats, suggesting that MCH is an orexigenic
peptide (9), while chronic infusion of MCH or MCH analogs sig-
nificantly increases food intake, body weight, white adipose tissue
mass, and liver mass in mice fed a moderately high-fat diet ad libi-
tum (10, 11). Further evidence of the significance of MCH in
feeding came from studying the effects of altering the MCH lev-
els using knockout and overexpression techniques (12–14). It has
shown that ablation of functional MCH results in a lean pheno-
type, increased energy expenditure, and resistance to diet-induced
obesity. Such phenotypes are not observed for many other neu-
ropeptides, suggesting a crucial role for MCH in feeding behavior.
On the basis of these data, MCH appears to be a critical effector
of feeding behavior and energy balance.
MCH ACTS THROUGH GPCRs
Despite the discovery of the MCH peptide, the site of its biological
action remained obscure until 1999. At that time, five independent
groups, including us, identified that the MCH receptor (MCHR1)
was SLC-1/GPR24, an orphan GPCR, by applying orphan recep-
tor strategies and reverse pharmacology (15–19). MCHR1 belongs
to the γ-group of rhodopsin family class A GPCRs (20), and
shows 40% homology with the somatostatin receptor as its closest
neighbor. High expression of MCHR1 mRNA in rats is detected
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in most anatomical areas implicated in the control of olfaction,
such as the olfactory nerve layer, olfactory nucleus, and tubercle
(21). Strong labeling is also detected in several limbic structures,
such as the hippocampal formation, septum, and amygdala, all
of which are implicated in the regulation of stress and emotional
processes. Furthermore, MCHR1 is abundantly expressed in the
nucleus accumbens shell, where it may play roles in the regula-
tion of motivation and reward. In recombinant cell lines, MCH
binds to MCHR1 with affinities of ∼1 nM, and couples to Gi, Go,
and Gq proteins (15, 16, 22). Thus, activation of MCHR1 leads
to increases in intracellular calcium mobilization via both Gi/o-
and Gq-coupled pathways and to decreased cyclic AMP (cAMP)
levels via the Gi/o-coupled pathway. Further analyses of MCHR1
signaling in recombinant cell lines and hippocampal brain slices
demonstrated that activation of MCHR1 also leads to extracellular
signal-regulated kinase (ERK) phosphorylation (22, 23). Recently,
accumulating evidence has supported the notion that receptor-
binding partners regulate the magnitude, duration, and spatial
components of GPCR signaling. MCHR1-binding proteins have
also been detected and described. Periplakin and neurochondrin,
which interact with the proximal C-terminus of MCHR1, reduce
the capacity to initiate calcium mobilization (24,25). Furthermore,
RGS8, one of the GTPase-activating proteins for Gα subunits, was
identified as a negative regulator. Arg253 and Arg256 at the distal
end of the third cytoplasmic loop were found to comprise a struc-
turally important site for the functional interaction with RGS8
(26). Clarification of the physiological consequences of these pro-
teins that interact with the MCHR1 system will be achieved by
assessing their coexpressions in the nervous system.
A second MCH receptor (MCHR2) was subsequently identi-
fied by six groups using human genomic sequence searches (27). It
shares 38% amino acid identity with MCHR1 and binds to MCH
with high affinity (28). The distribution of MCHR2 in humans
is relatively limited, in that it is expressed in the cerebral cortex,
amygdala, and hippocampus, but not in the hypothalamus (29).
In contrast to human MCHR1, human MCHR2 only couples to
Gq protein, and the signaling is not sensitive to pertussis toxin.
Of note, MCHR2 was found to be a pseudogene in rodent species,
but is functional in dogs, ferrets, rhesus monkeys, and humans
(30). The physiological importance of MCHR2 remains unknown
owing to the lack of available animal models. Later studies identi-
fied three MCH receptor sequences in zebrafish and two receptor
sequences from fugu, barfin flounder, and goldfish in whole-
genome datasets (31–33). Moreover, based on predictions from
a preliminary genome assembly of Xenopus tropicalis, informa-
tion for four MCH receptors has been obtained (34). Phylogenetic
analyses of these receptors suggest that an initial duplication of the
MCH receptor occurred early in evolution, giving rise to MCHR1
and MCHR2. MCH receptors are only found in vertebrates (35).
Therefore, the characterization of MCH receptors from birds and
reptiles may serve as a valuable reference to elucidate the role of
the MCH system during evolution.
The gene for prepro MCH encodes two additional peptides,
NEI and NGE of unknown function. MCHR1 is the sole recep-
tor expressed in rodents, MCHR1 knockout mice may provide
confirmation of the role of MCH in energy homeostasis. To
date, MCHR1 knockout mice have been reported to exhibit an
obesity-prone phenotype (36, 37). In contrast to MCH knockout
mice, MCHR1 knockout mice remained lean on a regular chow
diet. On a high-fat diet, the mice gained less weight, characterized
by hyperphagia, hyperactivity, and hypermetabolism. To better
understand the role of MCH-MCHR1 system in energy homeosta-
sis, several structurally distinct small molecule antagonists for the
MCHR1 have been synthesized and tested in cell-based assays for
their selectivity and for in vivo potency in the rodent. Comprehen-
sive review of desired selectivity and efficacy of MCHR1 antagonist
in vivo should consult some recent reviews (38, 39). The majority
of studies indicated that the MCHR1 antagonists are effective in
different models of obesity in a variety of different rodent strains,
due to inhibition of food intake and/or energy expenditure (40,
41). Overall, both rodent genetic studies and rodent pharma-
cologic studies on MCHR1 have confirmed the importance of
the MCH-MCHR1 system for modulating energy homeostasis.
With the broad distribution of MCH fibers and MCHR1 in the
rodent brain, the physiological function of the MCH system is
not only restricted to feeding behavior. In accordance with these
observations, multiple rodent models have suggested functional
implications of the MCH-MCHR1 system in sleep, emotion, and
reward effects of psychostimulants (42–45). In peripheral tissues,
the MCH-MCHR1 system has been shown to play important roles
in pancreatic islet function and intestinal inflammation (46, 47).
POSTTRANSLATIONAL CONTROL OF MCH RECEPTORS
Posttranslational modifications are considered to be the primary
regulatory mechanisms of virtually all GPCRs. Since most GPCRs
are naturally expressed at low levels, except for rhodopsin, in vitro
eukaryotic heterologous expression systems are often employed
for their biochemical characterization, including the complex
posttranslational modifications.
The most well-understood posttranslational modifications
include palmitoylation, glycosylation, and phosphorylation. Most
GPCRs are posttranslationally modified with one or more palmitic
acids, a 16-carbon saturated fatty acid, covalently bound to cys-
teine(s) localized in the C-terminal cytoplasmic tail. The insertion
of palmitate into the cytoplasmic leaflet of the plasma membrane
can create a fourth loop named helix 8, thereby profoundly affect-
ing the GPCR structure and consequently the interactions with
intracellular partner proteins. Although a putative palmitoyla-
tion site has not been identified in mammalian MCHR1 (48),
the existence of helix 8 was predicted by a computational analysis
and its functional importance in the signaling pathway has been
experimentally confirmed in HEK293T cells (49, 50).
N-linked glycosylation is one of the most common forms of
posttranslational modification. The consensus sequences for N-
linked glycosylation,Asn-X-Thr and Asn-X-Ser, in which oligosac-
charides can bind to the asparagine residues, are found in many
GPCRs and are shared by almost all eukaryotic cells, including
yeast cells. The significance of these asparagine residues has been
demonstrated in various receptors, and they seem to play sev-
eral important roles including receptor folding, trafficking, and
stability, thereby allowing fine-tuning of the receptor function.
When Flag-tagged rat MCHR1 is expressed in HEK293 cells,
several characteristic immunoreactive bands of ∼35–65 kDa are
detected by western blotting (51). These molecular weights are
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higher than those predicted from MCHR1 cDNA sequences, sug-
gesting glycosylated forms of MCHR1. This notion is supported
by the fact that the N-terminal domain of rat MCHR1 includes
three N-glycosylation sites at Asn13, Asn16, and Asn23 (48), all
of which are conserved among the goldfish, Xenopus, mouse,
and human orthologs (Figure 1). We proved the presence of
FIGURE 1 | Amino acid comparisons of Norway rat MCHR1 and its
mammalian, amphibian, and fish orthologs. The accession numbers are
as follows: Norway rat (nr), NP_113946; human (hu), NP_005288; Xenopus
tropicalis 1a (xta), NP_001072243; goldfish (gf), BAH70338; barfin flounder
(bf), BAF49517. Common amino acids with rat MCHR1 are shaded. Colored
amino acids show individual motifs: orange, N-glycosylation site; green,
casein kinase 2 phosphorylation site; red, protein kinase C phosphorylation
site; blue, cAMP-dependent protein kinase phosphorylation site. The
numbers in parentheses show the sequence identities with the rat
sequence.
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oligosaccharides in MCHR1 by enzymatic treatment. Further-
more, single or multiple mutations of Asn13, Asn16, and Asn23
to Gln (N23Q, N13Q/N16Q, N13Q/N23Q, N16Q/N23Q, and
N13Q/N16Q/N23Q) caused pronounced reductions in the lev-
els of glycosylation of the receptor protein, and impaired the
receptor expression at the cell surface. In particular, the N-linked
glycosylation at Asn23 is necessary for the cell surface expres-
sion and signal transduction (51, 52). Mutation of residues other
than the N-glycosylation sites also caused incomplete glycosyla-
tion of MCHR1, and impaired receptor trafficking and signaling.
MCHR1 belongs to the rhodopsin family of GPCRs, and the
Glu/Asp3.49-Arg3.50-Tyr3.51 (E/DRY) sequence is a highly con-
served motif in this family. It was found that substitution of
Asp140 or Tyr142 to Ala (D140A and Y142A, respectively) resulted
in non-functional receptors without changing the high affinity
constant values in HEK293 cells (53). The cell surface expression
levels of both mutants were about 40% of the wild-type MCHR1
level, with pronounced decreases in the 65-kDa immunoreactive
band (highly glycosylated form). Different types of site-directed
mutants that exhibited much less glycosylation were found for
highly conserved Pro residues at transmembrane regions 2, 4,
5, 6, and 7 (P97A, P177A, P220A, P271A, and P308A, respec-
tively) (Figure 1). These mutations all produced complete loss
of signaling with lack of the 65-kDa immunoreactive band in
HEK293 cells (50). The importance of proper glycosylation for
receptor trafficking and signaling was extensively analyzed using
substitution of Thr255 to Ala (T255A), which is located at the
junction of intracellular loop 3 and transmembrane region 6 (52).
T255A was largely retained in the endoplasmic reticulum (ER) and
associated with the chaperon protein calnexin in HEK293 cells.
This arose through receptor misfolding, which prevented some N-
glycosylation. Interestingly, addition of a small molecule MCHR1
antagonist to T255A- and N13Q/N16Q/N23Q-expressing cells
led to functional receptors becoming fully glycosylated at simi-
lar extents to wild-type MCHR1. Thus, complete glycosylation of
MCHR1 is necessary to allow its efficient trafficking through the
ER and Golgi to the plasma membrane.
Ligand-stimulated GPCR activation, desensitization, internal-
ization, and recycling occur in a controlled cyclical process. Since
the magnitude and duration of ligand-induced GPCR responses
are linked to the balance between signal generation and signal ter-
mination, the endocytic pathway that starts with internalization
tightly controls the activity of GPCRs. The process of endocyto-
sis is promoted by agonist-induced phosphorylation of receptors.
Upon GPCR activation, several sites in GPCRs are immediately
phosphorylated by G-protein receptor kinases and other protein
kinases. The receptor phosphorylation and subsequent binding
of β-arrestin prevent consequent interactions of the receptors
with G-proteins, thereby effectively terminating the G-protein-
mediated signaling and initiating the endocytic process. The
endocytic activity of arrestin is also subject to dynamic regula-
tion by dephosphorylation and ubiquitination. GPCR phospho-
rylation usually occurs predominantly on Ser and Thr residues
within the C-terminal receptor tail and third intracellular loop.
In the intracellular loop of rat MCHR1, there are nine pre-
dicted phosphorylation sites, comprising two for protein kinase
A (Arg/Lys–Arg/Lys–X–Ser/Thr: S158 and T255), six for protein
kinase C (Ser/Thr–X–Arg/Lys: S151, S243, S246, T251, T317, and
S325), and one for protein kinase casein kinase 2 (Ser/Thr–X–
X–Asp/Glu: T342) (Figure 1). It has been described that the
Ser and Thr residues are phosphorylated in agonist-independent
manners in some GPCRs (54). However, to our knowledge, no
previous studies have identified whether MCHR1 is phospho-
rylated under basal conditions or in response to MCH using a
[32P]orthophosphate metabolic pre-labeling approach. On the
other hand, the results of a mutational study suggested the impor-
tance of several predicted phosphorylation sites in MCHR1 for the
receptor function. A triple substituted mutant in the C-terminus,
T317A/S325A/T342A, has no effects on the signal transduction
in calcium mobilization, but significantly prevents MCH-induced
receptor internalization through protein kinase C andβ-arrestin 2-
dependent processes (55). Since S246, T251, and T255 in the third
intracellular loop are all conserved in MCHR1 derived from gold-
fish, Xenopus, mice, and humans (Figure 1), they may play a critical
role in receptor function via phosphorylation. The T255A muta-
tion produces a non-functional receptor as described above (52),
while the importance of S245 and T251 remains unclear. Thus far,
we have preliminary data that point mutations at these residues
produce no significant changes in either the cellular localization or
calcium mobilization (Honda and Hamamoto, unpublished data).
It has been reported that the generation of phosphosite-specific
antibodies accompanied by site-directed mutagenesis and chem-
ical kinase inhibitors can provide more direct evidence for phos-
phorylation in GPCR-expressing cells (2, 3). Since rat MCHR1
possesses nine potential phosphorylation sites, a series of phos-
phate acceptor site-specific antibodies are potentially obtainable to
reveal the coordinated biochemical mechanism involving sequen-
tial and hierarchical multisite phosphorylation of the receptor,
similar to somatostatin or µ opioid receptors (4, 56).
FUTURE DIRECTIONS
The MCH-MCHR1 system has integral roles in many cellular
events, and represents an important therapeutic target. For exam-
ple, it may be targeted in strategies for developing treatments
against obesity and mood disorders, and possibly also for inflam-
matory diseases. Therefore, the regulation of the MCH system
by posttranslational modifications remains an emerging area at
the nexus of endocrinology with important implications for drug
development. However, our understanding of the regulation of
MCHR1 signaling by glycosylation and phosphorylation is lim-
ited (Table 1). At present, several methodological advances could
facilitate analyses of GPCR posttranslational modifications. In
particular, significant improvements have been achieved in mass
spectrometry (MS) and related procedures such as tandem MS
or chemical microsequencing, such that MS is becoming a major
tool for analyzing posttranslational modifications. Since purifi-
cation of hydrophobic membrane proteins has been enhanced
by the utilization of specific detergents and several enrichment
procedures, MS analyses could have broad utility, such as direct
identification of glycosylated or phosphorylated residues, even for
low amounts in GPCRs (1, 5, 57, 58). Moreover, it has been shown
that distinct cellular environments can mediate different glycosyla-
tion patterns in rhodopsin and serotonin receptor type 4 (5). For
example, rhodopsin is heavily and heterogeneously glycosylated
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Table 1 | Posttranslational modifications with cellular function in mammal MCHR1.
Region Mutant receptor Impact on MCHR1 in HEK293 cells Reference
Extracellular N-terminus N23Qa
N13Q/N16Qa ⇓ Mature glycosylation
N13Q/N23Qa ⇓ Cell surface expression (51, 52)
N16Q/N23Qa ⇓ Ca2+ mobilization
N13Q/N16Q/N23Qa
Intracellular loop 2 D140A ⇓ Mature glycosylation (53)
Y142A ⇓ Cell surface expression
Loss of function (Ca2+ mobilization, cAMP inhibition, ERK activation)
Transmembrane region 2 P97A
4 P177A ⇓ Mature glycosylation
5 P220A
6 P271A
Loss of function (Ca2+ mobilization)
7 P308A (50)
Junction of intracellular loop 3
and transmembrane region 6
T255Ab ⇓ Mature glycosylation (52)
⇓ Cell surface expression (retained in the ER)
Loss of function (Ca2+ mobilization)
Intracellular C-terminus T317A/S325A/T342Ab → Ca2+ mobilization (55)
⇓ Receptor internalization (protein kinase C and β-arrestin 2-dependent)
aThe consensus sequences for N-linked glycosylation.
bPredicted phosphorylation sites.
when expressed in HEK293 and COS-1 cells, but shows a sparser
and more homogeneous glycosylation pattern in its native retinal
tissue. Thus, these features remind us of the significant importance
of studying both heterologous and natural expression systems, and
offer a comprehensive view of the posttranslational modifications
in MCHR1.
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